drugset
Drugs / CNTX-4975-05
last change Jun 2020 re-read 9 days ago

CNTX-4975-05

also known as capsaicin · trans-capsaicin
Developed for
osteoarthritis, knee
Investigated by
Centrexion Therapeutics

Trials 4

today NCT03661996 · Ph 3 NCT03660943 · Ph 3 NCT03576508 · Ph 1 NCT03429049 · Ph 3
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03576508 Jun → Sep 2018 osteoarthritis, knee Centrexion Therapeutics Completed No outcome recorded
Phase 33 trials · 2 missed
Phase 3 NCT03661996 Sep 2018 → Oct 2019 osteoarthritis, knee Centrexion Therapeutics Completed No outcome recorded
Phase 3 NCT03660943 Sep 2018 → Jun 2020 osteoarthritis, knee Centrexion Therapeutics Completed Missed primary
Phase 3 NCT03429049 Jan 2018 → Nov 2019 osteoarthritis, knee Centrexion Therapeutics Completed Missed primary
Comparator or background therapy1 trial
Phase 1 NCT03472677 Background Mar → Jul 2018 osteoarthritis, knee Centrexion Therapeutics Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as CNTX-4975-05 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03429049 ↗
4

NCT03472677 ↗

NCT03661996 ↗

NCT03660943 ↗

NCT03576508 ↗
Known as capsaicin “CNTX-4975-05 (capsaicin)” NCT03429049 ↗
Known as trans-capsaicin “CNTX-4975-05 (trans-capsaicin)” NCT03472677 ↗
Route Other “intra-articular injection” NCT03429049 ↗